Borders don't have to matter, says start-up founder creating access to medicines

26 January 2018

Older readers will remember a time – only three decades ago – when HIV/AIDS treatments were under-researched and some of the medication out there was not always available in the USA.

This was a time when AIDS patient Ron Woodrof established the Dallas Buyers Club, smuggling unapproved pharmaceutical drugs into Texas for treating his symptoms, and distributing them to fellow people with AIDS.

Some 11 years after his death, Dallas Buyers Club became a hit movie, and a further 15 years later, that period in the 1980s seems a long time ago given that patients can now learn about lifesaving medications via the internet and social media.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK